ID
38074
Beschrijving
Two-Part Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Oral Dosesof the Enteric-Coated Free Base Formulation of Darapladib (SB-480848) ina Dose Rising Fashion and to Evaluate the Safety, Tolerability and Pharmacokinetics of Darapladib when Co-administered with Ketoconazole in Healthy Adult Subjects. There are 4 parts to this study: Screening, Part A, Part B, and Follow-Up. Part A contains 2 Sessions per day for day 1-10, Part B contains 1 Session per day for day 1-14. Each itemgroup contains information when it should be filled out. The itemgroups of the non-serious and serious adverse event forms contain additional information on the definition of a serious/non-serious adverse event.
Trefwoorden
Versies (1)
- 15-09-19 15-09-19 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
15 september 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Darapladib Evaluation Case Report Form GSK LPL107988
Vital Signs
Similar models
Vital Signs
C0439564 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
C0439659 (UMLS CUI [1,3])
C0040223 (UMLS CUI [1,2])
C0444930 (UMLS CUI [1,3])
C0038846 (UMLS CUI [1,2])
C0039155 (UMLS CUI [1,3])
C0038846 (UMLS CUI [1,2])
C0012000 (UMLS CUI [1,3])